Longevity Dr. Matt Kaeberlein, Kai Micah Mills, Dr. Alex Colville https://desci.nyc/transcripts/longevity-dr-matt-kaeberlein-kai-micah-mills-dr-alex-colville Automatically generated transcript. May contain errors. [0:00] foreign [0:27] involved and I'm not like I and I came here but it takes for other religions [1:10] um [1:36] don't existence it's interesting New Jersey there's a few other states all right [2:44] and then this is nice [3:11] foreign [4:12] thank you [4:22] thank you yeah it's important [4:59] yes [5:11] you don't know [5:36] questions let's all sit down here [6:02] um [6:19] he's cheers [6:48] thank you Super Cash [7:18] take a Lily Potter [7:51] you want sauce you know bad idea oh where um thank you guys all for coming here and thanks to our guests we're going to Jump Right In I'll just describe very briefly so this is the Deep Thai NYC Meetup um we do this like basically once a month and this is a special one because it's part of mainnet by massari and uh that's like one of the bigger crypto conferences that always happens to be in [8:32] New York and we are uh it's sponsored by DB Dao which is an on-chain database which allows you to basically put your data into a database and then tokenize it and then everyone who contributes to that database uh or earns equity in the database based on how much they contribute and then when it's the databases sold everyone that contributed gets money um and what's used in a lot of DSi applications all right so without further Ado this is a really special we have a killer lineup um on longevity uh by some experts there was a little bit of a snap through with our previous speaker he had a medical [9:13] emergency uh at 10 A.M today so there was a lot of shuffling around to make it work but we have three excellent and better than speaker better than the speakers we previously had um um so uh we'll first start off with Matt and he's going to be talking about a very similar thing to uh what Oliver is doing and then we have uh Cal who's going to be talking about cryogenics and the work that they're doing in cryogenics and then we have another person um Alex who does like VC and investing in uh DSi and these are like these are like the top experts in decentralized in uh longevity and it's going to be a very thing and I apologize literally at like [9:53] 10 or 11 o'clock we were scrambling all day to practice the other but we have we put it together and it worked out very well um so without further Ado uh Matt you can take it away all right cool um so thank you thank you hopefully you all can hear me okay uh I certainly don't know if it's going to be better than Oliver but it will absolutely be a different uh conversation let me see if I can share now oh boy Google Chrome would like to record this computer's we can hear you it's fine okay I'm just trying to do the share here not have screen recording business [10:37] no no joy huh you guys here sort of yeah all right we're gonna try and make it louder so so far the uh the share screen is not working uh try going into your Chrome settings and uh and and going to like allow permissions there should be something along those lines if not you can just send me your images yeah okay why don't I do that and maybe it makes sense to have Kai or or uh Alex [11:20] go first so we don't hold up the show here do you want to do that I'll I'll send it to you but do you want to do that or do you want to wait to get mine hi are you ready yes totally up to you guys either way all right I'm happy too just press and hold the door unless I unless I also can share my screen which will be very very awkward but uh I think we might be okay let's sing let me just do the whole screen here nothing might be the easiest way uh yeah I'm actually getting the same [12:02] same problem so let me uh [12:15] all right mine's on its way to you so hopefully you'll get it Expedition but I can actually start and uh just talk through some of the concepts while we're waiting for it to get there so I think what I would like to do is um I'm not really sure what this audience's background is in in longevity you're here so you're interested in longevity so I thought I'd give sort of an introduction to the biology of aging and why that's important and then tell you a little bit about a couple of things that [12:56] I'm up to so I've I've spent after about 20 years in Academia at the University of Washington um studying the biology of aging from a sort of basic research perspective I've left Academia now um I'm CEO of a company called optispam which is really uh at at the Forefront I think of trying to enable the creation of tools that will allow a transition from what I am going to characterize as 20th century reactive disease care towards 21st century proactive health care and then I'll tell you a little bit about what we're up to at optispan and why I think that's important and then another company that we spun out of my lab where we're trying to develop Technologies to to hopefully really change the game and [13:38] Longevity intervention Discovery but just to take a step back um think big picture um I think it's useful to appreciate that when we look at how uh uh medicine pharmaceutical drug development even basic biomedical research has been approached really for the last 100 years it's been through the lens of disease and what I mean by that is that we have really focused on studying and attempting to treat individual diseases in isolation and I think the war on cancer is a perfect example of this where you know a large amount of [14:18] resources were dedicated towards the eradication of one disease and trust me I'm all for curing cancer or curing heart disease but one of the things that gets missed with this individual disease in isolation Focus major causes of death and disability in the United States and other developed Nations have at their root a single greatest risk factor and it's not the risk factors that we typically think about it's not how much you eat or how much you weigh or whether you smoke or whether you exercise it's how old you are and that's important because that tells us that there is a association between the biological [14:59] changes that happen with age and these diseases and if we can understand that biology that's driving the aging process we have the potential to actually intervene in that biology to modulate the onset and progression of many maybe all age-related functional declines and diseases simultaneously and that's really I think the promise of 21st century medicine and it is my hope and expectation that we will transition away from reactive disease care towards more proactive health care of which I believe the biology of Aging will play an important role in and um and hopefully I'll be able to share with you [15:41] um you know why I think that's the case um so I think it's useful to introduce a few terms that uh that are used widely in this field so the first term I want to introduce is lifespan did you not get it I sent it to you by email all right you can continue do you have it uh probably okay so uh so the first time I want to just introduce is lifespan that's really easy to understand it's quantitative there's [16:21] no ambiguity length of length of time from Life till death birth till death um and so I think life span's nice and we use it a lot in the field because it's really easy to measure and everybody knows what it means um the other term you may have heard because it's gained a lot of popularity recently is Health span Health span is a trickier term and I'll come back to this but I just want to make the point that um I think healthspan is really a qualitative term it's not a quantitative term and for now I'm going to Define it as the high functioning period of life and I'll come back and explain what I mean by qualitative versus quantitative um the last term I want to Define is geroscience and you may have heard of [17:03] this this just refers to the research aimed at understanding the biology that connects age-related functional declines and diseases um with the biology of Aging um okay so I can see I can see my slide deck now um do you have control of it are you you want to go to full full or slideshow mode or just sort of lowering it okay we'll make the best of it okay so I'm on Slide Five now okay Mission slide there you go okay so this is what we just talked about and I think it's useful just to appreciate that you know um the goal here I think most people would [17:43] agree is really to maximize that healthy period of Life push the diseases of Aging back as far as possible although it's also worth understanding that every intervention that we know about that targets the biology of Aging in laboratory animals when it successfully increases Health span it also increases lifespan so there's every reason to expect that these things will go hand in hand okay next slide please um so the uh I think it's useful to appreciate as well that there's been a lot of progress in the field in the last 20 years to the point now where we understand enough about the biology of Aging that we can actually put a name to many of the mechanisms that seem to drive the biological aging process [18:24] across the animal kingdom not just in people but in every animal where this has been studied and so these are the Hallmarks of Aging again you may have heard of this I'm not going to take you through there are now 12 of these things I don't think it's useful to go through and talk about each one what's important to appreciate is that these are shared mechanisms of Aging across all animals and in principle we know enough about these mechanisms to Target them therapeutically and have an impact on the biological aging process the other thing I think it's useful to appreciate is that these Hallmarks are connected and that's what the arrows on the middle are meant to illustrate is that there's an underlying Network here that we really don't understand very [19:05] well that connects these Hallmarks of aging and we know a few of the key nodes in that Network that seem to be particularly useful for modifying the biology of Aging but there's a lot we don't know next slide and that's really what this next slide is meant to appreciate uh or to illustrate is that I really believe there's a lot more that we don't understand about the biology of Aging than we do this is probably an over-exaggeration of how little we understand this is a map of the Known World in 500 BC and um you know there's this sort of vaguely europe-shaped thing and uh Asia exists and an oversized Libya and then if you sail too far you fall off the end of the [19:46] Earth I wouldn't say that this is exactly where we're at in understanding aging but I'm not sure it's much better and I make this point because if you if you listen to the popular press or even some people who have apparently impressive credentials in the field you may get the impression that we are close to solving aging or curing aging or reversing aging and I think it's a mistake to mislead people into believing that there's really no data to suggest that that's the case and in fact the data I would argue suggests that that we are very very far away from curing aging um so the other thing I want to say though is even though this map is nothing like [20:27] what the Known World actually looks like that doesn't mean it wasn't useful at the time that it was present right you could still use this map and I want to make the point that even though we have a lot to learn about the biology of Aging we can still do some stuff now to have an impact on the biology of aging and potentially quality and quantity of life for people next slide um so what do we know well we know aging biology is real we know we can modify it and we do that in every laboratory animal that exists we can select we can successfully increase lifespan and health span we also know that modifying the biology of Aging is more effective than targeting individual diseases in isolation we know something about the [21:07] biology of Aging we can put names to the Hallmarks we know some nodes in the network and the one that I've studied most extensively is called amtor there's a drug rapamycin that targets mtor that increases lifespan and health Span in every animal where it's been tested we know about some useful therapies to Target the biology of Aging again at least in laboratory animals and we're starting to get Clues outside of the laboratory in companion animals pet dogs in particular and in people and that's sort of where the field is at right now next slide so I want to talk a little bit about biological age because you probably have heard about biological age biological age clocks there are companies out there [21:50] that claim that they will tell you what your biological age is um so it's useful to understand what what that actually means and I I think one way to appreciate this is that there are lots and lots of traits phenotypes things that we can measure that change with age in humans and dogs and mice lots of things change some of those are at the molecular level we can measure changes in the Hallmarks of Aging if you've heard of biological age clocks they're probably referring to epigenetic age that's one molecular feature that we can measure that changes with age but there's a bunch of other stuff and I'm actually going to take a second and illustrate this using facial features so people have built biological [22:32] age clocks based on facial features it turns out if you take images standardized images of enough people of enough different ages you can actually create you can use AI to identify features in those images that are strongly correlated with chronological age okay how old somebody is um in in time and you can create a graph where along the line Y equals X you have your your features on the y-axis and chronological age on the excess axis and most people will fall on that line but not everybody some people will be above the line and the prediction is those people may be aging biologically more [23:14] quickly some people will be below the line the prediction is those people are aging biologically or slowly and if it turns out that in fact the people above the line turn out to be at higher risk for age-related diseases or mortality and the people below the line are at lower risk I think you can make a reasonable case that the clock is telling you something about health status and maybe about biological age and so all of these different biological aging clocks that's all they're doing they are measuring traits that change with age and making predictions based on a correlation with chronological age um and so that's useful to understand uh next slide please they're all doing that they're just measuring different things [23:54] what I think it's useful also to appreciate is what they can't do yet and this is where I think sometimes the enthusiasm gets ahead of the science at this point we can't use them to diagnose existing disease or pathology we can't accurately predict when you're going to die or when you are going to develop a specific age-related disease they can't do that yet I think the real limitation is they can't yet provide much actionable information Beyond eat a healthy diet exercise sleep more they can't really provide any actionable information beyond that and I think that's the limitation in where some of these things that are being stole sold to people are being misrepresented my [24:35] personal view is they also can't tell you which supplements to take and my personal view is if a company is selling you a biological age clock and then telling you to buy their supplement run away very very quickly that is dishonest um I think they also can't inform clinical trials yet but there's a real opportunity in the relatively near future by that I mean maybe five years that we will have some of these biological age clocks or biological age biomarkers that are useful in informing clinical trials and in intervention Discovery and I think that's there's a lot of potential power there once we get to that point next slide uh I have a question can you hear me yeah okay did you have a question oh God go ahead [25:17] go ahead we'll do it at the end okay all right cool um I also want to talk a little bit about health span so I mentioned that I thought Health spam was a qualitative variable and what I mean by that is that um we don't have a accepted definition on how to measure Health span the original one that you will still see used most often in the feet literature is period of life free from chronic disease and disability I used to use that definition as well I actually no longer like that definition for a few reasons because I think when you apply it to humans it doesn't really make sense first of all I don't want to be the one to tell every disabled person in the world that they have no Health span um I also don't believe that health is [25:58] binary meaning that it doesn't go from one to zero overnight I think we can all appreciate that Health changes as we go throughout our lives this is a made-up Health span trajectory for a made-up person this may or may not match my health span trajectory up till about the age 40 but you know I think this is representative of what we could draw this for anybody right so if you imagine your health is pretty high when you're young we all are feel bulletproof you know when we're when we're teenagers you get married you let yourself go a little bit you have kids you let yourself go a little bit more your health declines you get into your mid-30s you're like oh man I better do something about it I don't I don't want to be sick so you start [26:40] exercising you watch your diet your health can improve so that's one thing to appreciate Health can go up and down right maybe you let yourself go more in your 30s and 40s obesity sets in have your first heart attack in your 50s autoimmune disease stroke in your late 80s or late 70s and then you spend the last few years in very very poor health which by the way is where the vast majority of Health Care expenditures line up is in those last few years um I think this represents a more realistic view of of the average person's health hopefully not the health of the people listening to this call um the other thing I think it's useful to appreciate is that resilience declines with age meaning your ability [27:21] to come back gets harder as you get older um and uh and so I think we don't want we need to think about health more in this way and health span maybe as an area under the curve as opposed to a single thing that we can measure a length of time um next slide please so if we average this idea across the population so we smooth out the ups and downs we can actually start to get towards some useful population metrics of health or health span and I think it's fair to say that America was sick long before covid set in and what I mean by that is it seems as though life expectancy has plateaued it's been going up for a long time that doesn't seem to [28:01] be the case anymore across the population and I think we can make a case that Health span is actually decreasing there are certainly a lot more people living a lot longer with multiple age-related diseases so no question that six span is increasing about half of Americans have a chronic age-related disease and about 90 percent of Health Care expenditures go towards treating those chronic age-related diseases again as sort of evidence that targeting the biology of Aging could have a very large impact next slide please so one of my goals and I think the goals of the field is really to ask what can we do to push out that Health span curve to help the average American average person in the world recapture what I [28:42] call the Lost decade the at least 10 years probably closer to 20 years that most people are giving up of reasonably good health obviously it's going to be very difficult to get to the point where everybody lives in perfect health till 80 years old but conceptually I think this is what we want to go after I think this is largely achievable today through a combination of preventive Diagnostics personalized lifestyle interventions and generation one geroscience biomarkers and interventions and that's really what my company optispan is geared towards creating the tools that will hopefully help enable this next slide please so our goal and again it's optimistic our our big hairy audacious goal is Optimal Health spans for everyone or at [29:23] least everyone have the opportunity to achieve their Optimal Health span um so I've talked about how I don't think that reactive disease care is is the future that we need to get towards proactive Health Care There's A Better Way 21st century medicine is the better way biological aging is the core of Health that it's modifiable and I think we have some tools right now next slide so what are we doing again we're trying to create this toolkit that will enable medical providers and corporations that want to to to to achieve Optimal Health span we think that providers are going to be critically essential to this I don't think that [30:03] direct consumer is going to work in this market we believe the solutions must be scalable and they're largely based on what Lee Hood really coined as P4 medicine predictive preventive personalized and participatory but with the added science of geroscience I also want to say I think the fifth P has to be pragmatic we can't measure everything we're not going to change we're not going to get everybody to practice an optimal lifestyle so we have to be pragmatic about this and we're starting in two domains we actually have an active corporate wellness program right now within a company called Sabi Corporation where we have about 80 pacesetters in the program seeing I think some pretty compelling positive results in that context and we're just spinning up right now what we call our [30:44] Trailblazer program which is I think in at least in my view going to be among the top three or four longevity medicine practices in the world because we're really bringing what's lacking in what what I view as most of most of the current longevity clinics are really science and evidence-based approach next slide and to give you a feel I don't have time to tell you about all the stuff we're doing but just to give you a feel about of how we're approaching this we think that comprehensive Baseline Diagnostics are important biological age testing is important with in informed and actionable insights personalized intervention plans repeat measurements towards Health span optimization and [31:26] this is just one example of how we think we've got some insights into which individuals may be more responsive to rapamycin use for the purpose of improving Health span and I'm happy to talk about that specifically but um I don't really want to take time to do that right now next slide so that's the last decade and then I'll just finish up by talking about the longevity dividend and this isn't the original um use of that term but I but I'm going to coin it to say how do we get Beyond just squaring the curve for health span and I don't think the current crop of euroscience interventions will get us there I think we need better interventions and we need ways to find [32:06] them and that's where Aura biomedical comes in which is a company that we've spun out of my lab that is now up and running next slide and this is really based on um being able to scale longevity drug Discovery so we have created a system that we believe will allow us to do a million longevity intervention experiments in a few years and just to put that in context the largest database of Quantified longevity experiments in the world is called drug age it's open access you can go you can go right now to the drug age website has about a thousand longevity experiments in it this technology will increase that scale [32:48] by three orders of magnitude just in the last six months the three guys at Aura really only one person doing the the the longevity um experimental work has exceeded the rest of the field combined using this technology it's very simple I'm not going to take you through it but again I'm happy to talk about it with anybody who's interested it's it's robotics coupled with AI um uh to already do more than what's in the drug age database so there is really no question in my mind that this is doable um and so the company right now is in the process of raising money to go out and do the million molecule challenge why do we want to do that um I think the reason why is the data to [33:30] my view is clear the longevity field has stagnated in terms of intervention discovery the longest non-genetic intervention in mice in terms of lifespan effect was it a caloric experiment caloric restriction experiment done in the 1980s by Rick weinrich and Roy Walford the largest effect from a drug was a rapamycin experiment that we did in in my lab and we've known about rapamycin since 2006. why aren't we finding better longevity interventions every month because nobody's looking that's my view that's my opinion we need to go out and look and that's why we built this okay I'm going to skip the next couple of slides because that's just just showing you that we can do it and telling you [34:10] about the wormbot and I'll just finish up with the last slide which is this one so I know I know a lot of you probably were hoping and and Oliver may have told you what you should do now which is different than what I'm going to tell you but I'm going to tell you number one you should invest in your health like it's your greatest asset because it is when you don't have your health nothing else in life this is good um the first thing you want to do is not die that's really rule number one of longevity um but get me getting beyond that um what do you need to do I think Baseline and preventative Diagnostics are really important you want to know where you're at you want to make sure that you're not going to die from something in the next few months that's preventable or next few years that's [34:51] where you have to have a really good core set of Baseline and preventive Diagnostics you got to find a good Doc and that's hard but really what you want to look for is someone who thinks prevention rather than repair shop and who can appropriately balance risk reward I wish I could tell you that lifestyle doesn't matter but it does that's an important piece of this I think you've got to educate yourself and identify credible sources of information again that's really challenging in this space I would point to Peter attia as probably the most credible source of information in this space in my view right now and I talked about optispan I talked about our Trailblazer program we're going to be enrolling 100 people in this program in the next year space [35:34] is very limited but maybe you want to consider becoming a Trailblazer if you do you can find me shoot me an email and we can talk about it okay I'll stop there I'm sorry if I went a little bit over but we had some technical snafes so I'll uh I'll blame it on that thank you I'm deeply offended that you overlap on one of the slides you mentioned uh like biological thoughts uh does that refer to like getting like your A1C check or are you talking more about like your telomere lengths and good question audience yeah so so there's a couple things I would say on that um you can definitely [36:15] create and and people have created biological agent clocks off of blood work right so I wouldn't say A1C alone is not a useful biological aging clock because the correlation with age there is so weak that it's got basically zero predictive power but you can combine blood measurements to create uh biological agent clock pheno age is an example of that that um that I think you know uses I don't know 10 different blood measurements from a typical CBC chem panel but you most of what you'll see if you if you hear about biological age clocks are things like these epigenetic age clocks that companies are selling where you give them a mouth swab or some blood send it away [36:57] they will measure your epigenome and give you a number back that is supposedly your biological your biological age so that's the most common one there are lots of these things that you can use to measure different aspects of Bio what people are calling biological age which I think represent Health in some way but we don't really understand whether they're how to what extent they're measuring what aspects of biological aging does that is that helpful yeah it's helpful I just didn't understand um when you said there's like no supplements available for this but if you're talking about these like online services uh that makes more sense well the other thing I would say is it uh [37:37] supplements can be useful for certain things right so like if you're deficient in vitamin D a vitamin D supplement can help did that slow your aging process I mean unless you've got some reason to believe that it did some some actual data you wouldn't think that right so I think what I'm saying is there's no supplement out there that in my view convincingly has been shown to modulate the biological aging process in humans there are some where there's some reason to believe that they could and you know it's up to each person to evaluate the risk reward there um there are a lot where I think they are purported to have that effect where the data is actually much much weaker right so we could go through a list of [38:18] supplements and talk about the the strengths and weaknesses for each one but I think anybody who's being honest will say there are no supplements that have been you know clearly shown to positively modulate Health span or lifespan in humans okay yeah I agree right I've got another question back here um so longevity tends to be like a rich man's game what's being done in a space to make it available for everyone I actually don't yeah that's a really good point because I think that that sort of gets perpetuated in the media I would say longevity okay so first of all the the things that we know for sure that anybody can do right now to improve [38:59] their health span and probably their lifespan are not a rich man's game right they're the things that and I get that there are there's disparity in health care no question about it I'm not going to try to minimize that but a lot of these lifestyle things anybody could improve their lifestyle to give themselves a better chance at at a longer healthier life the reason why healthy diet and exercise and good sleep quality work is because they target the biology of Aging so honestly from that perspective it's not a rich man's game I think what you're alluding to is the concern that when we have a let's say a drug that targets the biology of Aging that where confident works right let's say it's gone through a clinical trial [39:40] that that's only going to be available for rich people right I think it's impossible to know for sure if that's the way that this will play out but I would also say that's really no different than any other aspect of healthcare I mean that's true for a lot of prescription medications and I don't think that longevity is going to be unique in either direction there I think there's some reason to be hopeful because of drugs like rapamycin which again is in my view the current Best in Class for a potential longevity drug for people because rapamycin is off patent and there's a generic available I'm not saying it's cheap but it's not only going to be available for billionaires [40:21] right so I don't I think it's a little bit of a myth that longevity is only is only for rich people um but I do think it it's it is the case that there are important disparities in health care and I don't think longevity is going to be unique there it's going to be like any other aspect of healthcare I would love to see that change but I you know it's it's a big problem is anyone looking into instead of trying to like uh rejuvenate the body to replace the body so like the immune system and grow in Oregon or a lake or an eyeball externally reverse so I there are absolutely people trying [41:03] to do pieces of that right it's it's a very very difficult problem to think about doing it for every because you have unique challenges with each organ and tissue that you're trying to grow you know in a lab or synthesize in a lab and then transplant into a body so I will say one thing I didn't have time to get into epigenetic reprogramming this is an area of the field that people are very excited about again I would say they are overly enthusiastic about it but it is it does have the potential that you can actually within the body through remodeling the epigenome at least partially rejuvenate tissues and and organs and restore function in some aspects of youthful function we don't know yet how easy that's going to [41:43] be but there are people doing that as well so so I think it is a valid strategy it is just very very difficult from a biological complexity component the last thing I'll say on this is you know where I think that problem becomes very very challenging is in the brain even if you're successful in the rest of the body if you I mean talking about trying to replace the brain um and what that means for are you just changing the entire person right I mean then you get into sort of philosophical arguments but yes there are people working on that my personal view is we're very we're much further away from being able to do that I think we're much closer to being able to using drugs and maybe some Gene therapies have more [42:24] modest effects but still pretty significant effects on health span and lifespan in people and that will actually be our next speaker is uh despite Gene Herbert who got Einstein who's looking on rejuvenating like uh for brain tissue hey thank you so much uh that was really helpful to continue to work okay thank you again all right next up we have um Kai he's doing cryogenic work very interesting stuff so Kai without further Ado take it away thank you [43:08] hey guys hello hello can you hear me good um first of all yeah happy to be here thank you thank you um it is an honor to be sandwiched between uh Matt and Alex it's definitely a uh an awesome lineup that you have here um and I love a lot of the points that uh you know Matt touched on throughout his presentation I think there's uh there's a lot of those points that um you know I came to similar or the same conclusions on and it's actually what uh you know is one of the driving factors of me actually going into the uh you know crowd preservation field um as opposed to uh working on working on Aging or different parts of longevity [43:50] uh and I will say props to whoever brought up uh you know replacement work um because if I if I wasn't working on cryo I would probably be uh spending my time in in that space um Matt's definitely right there's a lot of huge challenges um but uh it's just I think it's a really exciting area um and I think I was actually talking to Jean Haber um you know which which you brought up not too long ago um but yeah I suppose we can uh we can jump right into it um uh if you want to go to the next slide here uh I just want to talk a little bit about um our end goal right what is the what is what is the reason for um for working on on cryo and cry [44:31] preservation because of course there's uh there's there's different uses in uh uh you know quite a few use cases for for crybiology and crab preservation but um you know the end goal here is to get to the point where we can cry preserve the human body or at least the human brain um uh and and keep it in a form of you know uh uh a sort of stasis a a way to uh pause biology until we can um sort of solve what we need to to fix uh you know the causes of death and also bring them back from from crowd preservation uh and and you know uh what what Matt said as well is you know we do need to be realistic about um how difficult of a problem uh aging is right um how how much uh how much work needs to be done there how how far [45:13] we have to go um and uh and and we're still dying you know we're we're we're dying every day we have uh are our parents our grandparents and and so on so um uh you know this this is essentially some people call crap preservation uh uh you know an attempt of being an ambulance to the Future right uh we sort of want to we want to keep people in stasis until uh until we can uh until we we can we can solve those problems that we need to solve um next slide please and uh yeah I touched on this a bit but yeah I mean we're we're dying there's there's no way around it that's uh that's that's what's happening that's why so many people are working in in the Aging field and um uh you know uh obviously there's [45:54] there's there's different motives but um uh you know for those of us who don't want to die um we're we're up against kind of uh you know a beast here right where we're we're pushed things like uh like biological age tests like uh you know supplements and diet and exercise and the fact of the matter is it's it's not going to increase uh maximum human lifespan right uh you know there's there's a lot of work to be done and um you know until we can until we can uh you know solve aging cure aging whatever you wanna whatever you want to say um uh and and not only aging but but many other causes of death outside of Aging uh we need a way to be able to put biology on pause right um uh this is a problem that's [46:34] exceptionally underfunded uh is something that's really not taken seriously by a lot of people um back when I was first entering this field and I I uh by field I mean life extension in general and I was I was trying to figure out where I'd uh you know be the most help and where I could really make the most difference I kind of made this Tech Tree and tried to lay out the field and see where the funding was going and see where companies were being spun out and um you know found that that crowd preservation was uh you know you know I mean I mean practically empty right like very very few people uh uh working on this problem and it always it always uh it was shocking me because crap preservation you know I like to say that even if we cure aging we're solving the Aging problem whereas uh if we can if we [47:15] can solve you know reversible crowd preservation of the brain of the body um we're really solving the death problem right we're we're uh you know it doesn't only cover um uh you know dying of Olay age or diseases of Aging um uh but rather most causes of death it can actually uh it can actually handle um uh so yeah next uh right so the question is where are we right where are we right now um uh you know these These are three of the papers that um I've I've uh you know have really stuck out to me over the past um uh over sort of the recent past [47:56] um uh biostasis.com has an amazing sort of list of all the big you know breakthroughs over the years and um uh but these ones are super exciting because back in you know 2009 Greg Fahey was able to uh cryo preserve recover and then uh transplant that uh rabbit kidney into into a rabbit and have it work perfectly fine and have have the rabbit uh basically get to a point where um it was going to live you know indefinitely the the the uh the kidney wasn't wasn't uh you know it was fully functional and being used by the by the rabbit after undergoing you know down to crab preservation temperatures uh and and coming back um uh this this second one here was was really interesting because uh we were able to prove that uh you know long-term [48:38] memory at least in C elegans of course a much more um you know simple Beast than humans but uh uh you know when they were trained to avoid a certain chemical and then cryopreserved brought back revived and uh uh you know they were they were able to show that that they're training from before um persistent through crowd preservation so um really just uh you know not that even complicated of the study but but I feel like the the implications of how you how you really think about um memory and going down to these you know this state where we're where biology is practically halted um is is is just really interesting and then uh you know an incredible one back in 2015 from uh or Robert McIntyre was [49:19] aldehyde stabilized crowd preservation where we will we were able to show that um uh we could crowd preserve an entire brain uh down to the very fine structure of that brain uh and and have it be perfect throughout the throughout the entire brain so um uh yeah we're we're a far you know way from just uh throwing people in the freezer um you know there's there's been some some really tangible and exciting breakthroughs in this area uh next slide please right so uh what are we doing um these are the first two research projects that we are funding at uh cryodao um essentially cryodao is is is it [50:00] exists that for that purpose right we are we're here to uh fund these sort of uh you know uh uh more risky and and exciting projects in Cloud preservation that are not going to get funded uh practically right now through through anything else right you're not going to get government grants to work on these types of things um uh sort of these these uh uh these four these moonshot kind of projects in in crap reservation uh so this this first one here um is sort of uh uh Less on the cooling downside and more on the uh recovering the rewarming side so um you know one of the big problems In Crowd preservation is obviously bringing things out of craft reservation whether it's in Oregon whether it's a person an animal and so on [50:40] um and so we're working with uh uh Ramon Risco who sort of has this this novel approach of rewarming uh large organs and just a really uh you we're basically taking like thousands of ultrasound transducers and and um you know almost making like a very smart microwave and you know uh uh so um you know maybe maybe uh we can stop having the the inside of our uh uh you know Hot Pockets be be cold um and then this this second one here is is sort of a you know a a medication that we're we're working on that that is applied prior to product preservation um so before the process even starts this is uh something that we can introduce um so it's something that's [51:21] that's very different at all you know cryonic facilities and it's something that's not standardized um and and to this point has honestly a lot of it's been been guesswork so this um uh is gonna make sort of a a really a really big leap in that area um so those are the few that we're funding um right out of the gate uh and if you can go to the next slide um uh this is actually a little outdated we are still um looking into these projects but we have a lot more uh you know deal flow of scientists who are coming in a lot of them actually coming from the longevity field who are sort of getting less confident with sort of the progress in the Aging field over time and wanting to jump over and do work here so these two are are really [52:01] exciting persiflation uh in in sort of early tests uh a while back show that you know it might be able to uh recover even pig hearts you know very very large tissue structures um from from you know negative 120 130 uh sort of these these very low temperatures um uh and then you know we're also uh similar to the uh you know C elegant test of of uh showing that their memory was retained to crop preservation um uh Laura Jenks wants to uh sort of uh prove the same thing in in mice so that's that's another project that we've been uh sort of reviewing and looking into but um there's just a ton of exciting uh uh work in this space to fund and and we're [52:42] really you know one of the only ones um uh funding at least at least publicly so uh next slide sorry uh yeah so there's there's no shortage of um of issues to solve right uh you know uh crowd protectants being toxic uh uh you know fracturing that still happens um you know there's there's a huge list of uh and a lot of it is is really uh you know there's quite a bit of low-hanging fruit uh in this in this field uh like I said it hasn't received the attention that it deserves it hasn't received uh the funding that it deserves so there's there's a lot of these problems that we can we can jump into and and uh you know without needing you know billions and billions of billions [53:22] of dollars uh make a really huge impact um on on this science but yeah I mean that's just a list that we could fit uh you know in a slide at a tech size that you can read um there's there's there's so much so much more Beyond this that we can we can jump into um so yeah next next slide please you might have seen um uh I mean it's it's a it it's it's D Side New York you know so I'm sure you're you're familiar with the uh sort of standard Desai uh flywheel and and you know we're we're we've really you know uh tried to model um a good amount of what we're doing after uh you know Vita Dao which is about to add a lot of uh success in [54:04] funding you know a lot of really exciting projects in the Aging field and um so you know really really kind of following that that same uh idea of you know monetizing that research commercializing the research that comes out of cryodao um having those proceeds go back into the Dow and then uh you know funding funding more more exciting research and having the community be really involved in pushing this forward because uh yeah I mean there's not a lot of traditional funding um for this but there's there's a lot of people who are excited about cryo about organ preservation about cryonics um so there's there's a really kind of uh you know strong Community coming around it to put it together if you go to the next slide you can um you know see some of our some of our team members here some from Vita how uh [54:44] you know Allison for foresight of course Emil and I have have chronic facilities in in the field and um yeah so just just just uh uh and there's there's a lot more of us now um uh which which you're welcome to you know go go take a look at on the website um and then of course our uh scientific uh advisors a couple of these guys you know Ashwin and uh Ramon risko are actually the two um you know our first projects that we're funding uh in in the field so um and yeah yeah that's that's pretty much it so that's um that's what we're working on that's what we're funding uh you're welcome to um you know join us come check out the website Discord whatever uh and uh uh yeah yeah thank you thank you for having [55:26] me [55:36] do we need any equipment I have uh a lot of gear including like electric microscope and and other stuff you know robots uh what what do you need are you asking me what we need the equipment we need yeah yeah student projects if you if you finance Ashwin is it Ashwin they walk right yeah uh yeah like uh what is his requirement in terms of project yeah yeah so so Ashwin he runs um sort of a a private lab that is working on improving crowd preservation procedures um so he has he has the equipment he needs already because he's he's been [56:17] he's been doing these uh you know working on you know various different things he he wrote the the Alcor manual on crowd preserving humans right uh so he's very uh you know intimately familiar with the process um so so yeah I mean you know especially with the funding he'll have everything we need uh he needs to to do the project um but I appreciate the offer you know and uh uh yeah any other questions [Music] do you think we'll get to a point where the cryo preserve people prior to their deaths like while they're alive and healthy [56:58] yeah so it it really um you know it depends how you how you define uh you know alive right because um if you were to uh if someone's you know heart was to uh stop beating um and and you know uh they may be dead for for let's say you know 30 seconds um and then they can be resuscitated uh you know were they really dead were they temporary temporarily dead right so that's that's kind of the distinction you have to make so when when you know the the ideal case um in cryo and and you know if we're doing uh you know if we're doing craft preservation in in the lab um it would be directly after uh [57:40] euthanasia right because at that point the body is not um in a state that is any more dead than it was three seconds ago right um and uh and and you you'd certainly run into a bunch of you know uh ethical uh issues because the the process of starting cryopreservation would would kill you or you know uh the the animal or whatever else so there's there's just no there's no difference in in um them being freshly dead or or Alive um so I hope that that answers the question do you think it's harder to revive d uh sorry sorry harder to revive what the [58:22] brain or the body like uh yeah I mean when we when we talk about whole body you know crowd preservation where we're including the brain in that right at the end of the day the brain is is you know the uh really what matters uh you know more more than anything else um there there are there are specific challenges with the brain right um being being able to uh uh uh you know crime preserve uh uh the brain I mean you have to you have to um sort of uh you know one of the problems with crowd protecting is uh uh you know the molecules are are oftentimes too large to pass through the blood-brain barrier right um and and this can make it difficult to get really uh you know quality crowd [59:04] preservation of the brain um you know and and you know uh when it comes to field cases of of uh humans you know it's it's that this is is made you know quite a bit worse right uh it's really difficult to get to get quality Uh crap reservation of humans uh uh because we don't get euthanized right it's a lot of times our death is random and so on but um uh yeah yeah it's uh I I think it's it's it's reasonable to say that the brain is going to have really unique um challenges when it comes to innately reversible crowd preservation um but the body being uh you know having so many different uh uh different types [59:44] of tissues and um uh uh just the scale of the body and and you know these these different these different uh you know aspects make it make it you know very hard as well so uh which one will have you know uh the whole body without the brain or the brain first um it's actually hard to say it's hard to say [1:00:17] if we find um and I see this because their essay and it says [1:00:32] um yeah yeah so so yeah and I and I will say you know uh we're all terminally ill right now which is you know the the unfortunate part uh we're all dying of Aging but um but absolutely I mean you know especially in in cases uh where this would be uh uh you know really you know cases that that would really be life-changing is is um you know uh uh kids that have some sort some sort of um you know currently incurable uh type of cancer or um uh some sort of uh you know terminal [1:01:13] uh disease right um where where they can they can sort of just just be paused until um we can we can sort of cure that that disease or you know whatever that that cause of death was that time um and then and then bring them back so um yeah I mean I mean you know that's that's a huge uh you know possible use case of cryo in the future is is people with terminal diseases yeah yeah excellent thank you so much yeah thank you thank you for having me [1:01:55] um good to see you again yeah likewise good to see you again uh and thanks so much for for welcoming to speak with two amazing people Matt and Kai that's a hard 2x to follow No Doubt thank you well um Alex is a VC a former PhD student at Stanford and uh now I'm doing uh age one and I'll I'll let you take it away from here yeah perfect and I actually I'm gonna try to present if that works for you we'll we'll see how that goes but let me know if it doesn't work [1:02:41] um can you see this yes okay perfect uh and it's kind of a funny transition from Kai's talk and that uh what I was doing in essence in my past role for the past two years I was the founding chief of staff and investment manager at a family office uh called amaranth Foundation where we were probably the only other public investor into the cryo space uh in terms of actively funding grants for cryobiology and and cryo preservation so A fitting transition in part um maybe I can start by talking a little bit more about kind of the other things that we did at the Ameren Foundation as [1:03:23] kind of background uh but this was a in essence a family office that's focused on advancing moonshots in the Aging field that kind of branched across all the different areas that were touched on today uh a couple of which I'll focus on and a couple of these slides but this branched from from cryo to replacing aging to trying to push along kind of new ways of regulatory structure of how to Target aging directly in humans so kind of wide a wide variety of projects uh wherever we thought there were core kind of bottlenecks to pushing the field forward previous to running this family office and actually during running this [1:04:04] family office I was a PhD student at Stanford studying the biology of aging and Tom rando's laboratory and previous to that got my start in the Aging field and David Sinclair's lab back in 2014. so that's kind of my aging trajectory about 10 months ago I was brought in by my colleague Laura Deming to help her build the next Fund in the series from the longevity fund and I have in essence a background slide on on Laura and the longevity fund here in essence where she formed the longevity fund back in 2011 this is a very inaccurate photo in that at the time she was 16 years old she [1:04:45] went to MIT when she was 14 years old dropped out at 16 to start the longevity fund and ever since has been investing in the fields for the past 12 years formed a second Fund in 2017 she formed an accelerator program in 2018 that was an experiment to try to democratize building a longevity biotech company in essence providing more support and resources to unconventional Founders to build in the space that kind of experiment led to a lot of companies that we are absolutely obsessed with a couple cool examples fauna biotechnology which is working on translating insights from [1:05:27] hibernating species to humans and potentially hopefully uh hibernating humans in the very long term another cool example that I'm obsessed with is loyal which is a company working to extend dog lifespan and and kind of proudly related to to Matt's dog aging project in a sense is really using dogs as a model organism for humans for all the amazing features that they have in terms of shared environment and shared food in some cases uh and they made news back in March uh by the first time ever in essence getting the FDA to sign off on their pivotal trial design uh in essence giving them what's called [1:06:08] protocol concurrence to be able to Target aging directly as a hard endpoint and if that trial is successful they'll be able to in essence make a label claim for aging and health span something that has never been done before in any species which would be really cool um so yeah that's kind of uh the background of the longevity fund and about 10 months ago Laura and I got really excited about building in essence the next Fund in the series to be in essence doubling down on this theory of democratizing longevity biotech uh and trying to catalyze new talent and ambitious talent to come into the space um would Echo a lot of points that Kai [1:06:48] made in terms of the field being a little bit stagnant in terms of bringing the latest tools Technologies brightest Minds into the field uh the lens that I take to the Space is really one that focuses on talent I am a very strong believer that Talent is the biggest bottleneck to progress in the Aging field this was actually something I worked on a lot at that family office role of setting up a program called the time Initiative for undergraduates who are interested in a fellowship to explore the Aging fields or get a summer Grant to work in the Aging field uh also helped fund a summer course on the biology of Aging at the marine biology Laboratories in Woods Hole Massachusetts [1:07:30] so take a very Talent focused lens to the field and that's definitely core identity at uh age one um and so actually we just launched the fund two days ago so this is my first time talking since the fun Lodge uh we lodged with a 35 million dollar fund and hoping to have a 50 million dollar fund by the end of the year um and I've already made three Investments out of the fund uh that we are very very excited about uh across the different ranges of things that have been talked about today uh but I figured I'd give a tiny bit more background in in terms of kind of what our vision is for the Aging field how we kind of really like view the space um this I think is is kind of hopefully [1:08:11] helpful graphic in terms of thinking about different core areas to work on in the Aging field uh so the first of which you just heard a great talk about pause how can we find ways to induce stasis in human tissues and cells and maybe that's through an ice cube and prior preservation or maybe that is through hibernation or induced torpor or diapause um another bucket uh which has been a long focus of the Aging field and really goes back to the core original days of the Aging field which is uh to delay or prevent aging um and so this is actually what initially set a lot of the modern field of Aging abuzz was this discovery that [1:08:52] in C elegans and worms you could modify and mutate just a single Gene and and yields uh almost a 5x increase in lifespan in worms um and so that's a really cool bucket uh that we are excited about as well the bucket of restore is kind of bottom left as Matt cable line was alluding to with reprogramming interventions that might potentially be able to actually reverse and turn back the clock the evidence in this bucket is super weak at this point uh this was actually what I worked on uh during my PhD was this reprogramming for aging space still very very nascent but also would be kind of the ultimate [1:09:33] promising thing if we were to actually be able to attain it and then bottom right on this slide this kind of notion of replacement so if you have damage or aged cells tissues simply swapping them out with youthful ones that are derived from a synthetic embryo or derived from uh induced stem cells or embryonic stem cells so that's kind of like high level four buckets in terms of how I personally break down various interventions in the Aging field and these are kind of the main areas of focus for us as a fund um this is probably way too tiny to read but I'll try my best at a high level to describe uh the left column is the [1:10:13] status quo and the right column is kind of what we are really putting out a call to action for Founders to come work with us on um the first one is the fact that there's no regulatory pathway right now for creating aging uh interventions in humans and so I mentioned how loyal is dealing with this and dogs um I think we're going to see in the next 10 years the same transition happen in humans there are a bunch of potential endpoints in the works and it's really kind of up to pioneering Founders to really Thrive that home and actually take the big risk to go after aging directly as opposed to the current model of go after a single age-related disease [1:10:54] at a time uh which can lead to the risk of false fails and ultimately slow progress um there's a result as a result of that we have zero approved aging drugs so we want to fix that as a fund right now small molecule interventions are getting a vast majority of the focus of the FI of the longevity fields we want a longevity field to really Embrace regenerative medicine to truly diversify into Cell Therapy tissue engineering uh xenotransplantation tissue replacement and I think the founder archetype has been the biggest Focus for Laura for the past five years or so in essence how can you uh really diversify what a Founder in the longevity biotech space looks like [1:11:35] and I think to do that that's exactly why we're building H1 is to try to kind of build a fund that can instill the belief in Founders that may not have the same level of biology background or may not have the same level of Connections in Silicon Valley that a kind of a repeat founder might have so trying to really like democratize Founders and the longevity biotech space is a big focus of ours um the fact that right now funding in the space is kind of dominated by a few very very large super funded Vehicles like Altos Labs retro bio new limit we really want to see kind of the scrappy Founders be able to be supported to go on and make cool impacts on the space [1:12:17] and we've kind of seen it in our own hands with companies like loyal that it's really possible to make a tremendously outside sized impact starting out with just a very finite amount of resources in the space and then the last one is just bringing more rigor to the space trying to do a lot on the community building side trying to build edgy science into the Overton window into public acceptance this is a huge huge focus of ours I think people are not nearly as strategic as they should be on this front it's absolutely imperative uh in essence to think really really carefully carefully about how to get the public on board with in essence something that you think May ultimately [1:12:58] be beneficial to humanity uh and then the key there is obviously like ethics like make sure everything that you were doing is ethical um yeah I think the Aging field was dominated by this notion of the Hallmarks of Aging or like a variety of uh from a 2013 paper in cell a really kind of reductionist framework to the space and that's something that we're hoping to change people's minds about to get kind of more holistic and and kind of systems focused and how they view the field uh and then lastly for for kind of the last three a lot of them center around the fact that a lot of measures of Aging are very biased and cherry-picked and low throughput and so in essence how can we scale up the reproducibility of the field and uh [1:13:40] increase the amount of high throughput robust measures of Aging that we have at all levels the cell level the tissue level the organism level um these are are kind of all the problems that we are most focused on uh and so that at a kind of very high level is our vision as a fund and why we just launched this week uh and and so I'll I'll stop there and see if there's any questions cool does anyone have any questions for Alex uh where are you located and uh are you interested in the collaboration with [1:14:22] existing labs uh yeah no we definitely love talking to labs and professors uh we're located in San Francisco but we have team members spread out all over North America we've got a principal in Boston we've got uh some undergraduates in Chicago and Toronto and Michigan um and we love working with professors and Labs we routinely host uh events community events in Boston and San Francisco with professors uh you mentioned the one that we have not cracked yet but uh we actually are hopefully planning an event uh in New York in October so I will keep you all [1:15:03] posted about that uh maybe maybe through Michael uh but we're yeah hoping hoping to have a first event in New York there is actually a really cool aging community in New York through um an individual named Matt Sturgill that uh you guys may know but he runs a lot of Aging community events in New York I put his name in the chat and we can circulate that later how are you thinking about like these centralized science everything you've done in a lab or do you think that longevity has some ability to use people that don't have a PhD or don't work similarly foreign yeah really really good question [1:15:45] um we've got some really cool examples of Founders in our portfolio over the years that did not have a biology background and have gone on to build really cool successful companies in the Aging space so one of these is actually called Spring Discovery uh the founder Ben Caymans was the the first software engineer at Khan Academy had more of a software engineering kind of Ed Tech background but all of a sudden became very passionate and motivated by the Aging field became a founder and now is like series B Stage Company over 30 employees like just you know in essence has done a lot to create a really cool culture marrying [1:16:26] computational biologists and kind of computational folks with uh wet lab biologists and I think like his ability to do that was really driven by the fact that he was just like a very strong operator was really good at fundraising was really good at recruiting was really good at building a culture uh and I think that even though the Aging space is like highly highly highly technical as long as you're able to pair with scientists that have really good taste and find an early employee or or a kind of co-founder that has that really good taste in the science uh that anybody can actually make really big contributions to this field amazing does anyone else have a question [1:17:08] for Alex uh one last question Alex you said there's no FDA approved drugs for longevity but were you talking about the ones in your portfolio or just in general uh in general and in terms of like we've never had a drug that's been proven that it affects Aging in humans so there are drugs that we know extend lifespan and mice that are already FDA approved right so Matt talked about rapamycin there's metformin uh there's uh sglt2 Inhibitors there's uh in essence of a variety of different drugs that people are excited about that might have an impact on aging and the bottleneck is really like [1:17:50] testing them in a rigorous way uh because people just haven't done it which blows my mind because we've known for so long that these things affect Aging in animals and people just like for some reason like won't take that big ambitious shot to do it in humans to put anything to the test uh so as of now yeah we have no drugs that are have been shown in humans uh to impact aging uh is wrathomites been like Meadow like you know how metaformin the uh gp2 drugs we've got some Iceland are you are you asking about the differences between those classes of drugs between rapamycin and sglt2 [1:18:30] Inhibitors and Metformin well metaformin and the sgo t2 Inhibitors are both like pre-diabetes drugs right I don't know about rapamycin yeah so uh default to Matt came relied on anything rapamycin but he uh in essence rapamycin is an mtor inhibitor mtor in like the most grossly simplified way I could describe it is a master regulator of cell growth uh but in reality it's one of these proteins that's just like all over the place in terms of all the different interactions that it has uh but in essence rapamycin was FDA approved for immune suppression uh given at kind of higher doses than [1:19:11] people would uh think about taking them taking it excuse me for for aging and Longevity so it's more of like this immune suppression drug that people realized in mice ended up having a cool effect in lifespan okay cool thanks giving one of the problems is like dying takes a long time so that's makes it harder to test these things and like it's kind of kind of standardized clinical trial yeah I mean for sure it's like it's a tough problem from that sense that is definitely one of the core routes of the problem um but it's not insurmountable like I think people just aren't being ambitious enough like like cardiovascular disease [1:19:54] trials and Alzheimer's trials are also really long like it takes somebody there there are trials right now that are testing in essence prevention drugs for Alzheimer's disease and if you're already gonna run like this like six seven year Alzheimer's prevention trial there's no reason that we couldn't run like a five or six year trial for aging um it probably costs about the same amount of money that people are ponying up for these Alzheimer's trials uh but it's just that like no one has gone out and done it for aging yet because no one thinks it can be done uh it's like a mental barrier in part uh which is a big frustration of mine [1:20:39] I really do believe that's true um and I think it's gonna be really hard because you need to raise a lot of money so the the team trial is a trial that near bars lie an expert on Aging in New York uh at Einstein College of Medicine he's been trying to run this trial since about 2013. uh it's scoped out at about 50 to 60 million dollars would take about five to six years to run and the end point would be a composite a variety of different age-related diseases so they kind of frame the endpoint as multi-orbidity uh and the the endpoint is like a composite of like cardiovascular disease and dementia and mortality and uh diabetes um and uh I think that like [1:21:20] I think that that endpoint is great the FDA actually like signed off on that endpoint to some extent in that near and a bunch of his colleagues in the space went to the FDA said here's this like end point what do you think of it and the FDA was like sounds good uh and then they just like never were able to raise the money to actually run that trial on that foreman which would have like actually proved kind of that that was a feasible thing to do um so like the path is kind of sitting there in a sense and just like no one's taking it excellent all right thank you so much Alex that was fun [1:22:06] all right thank you guys and thank you Alex thanks so much Michael have a great night everybody said I'm not there cheers yes